Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.

Launched by ISTITUTO ONCOLOGICO VENETO IRCCS · Apr 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the financial impact, or "financial toxicity," that patients experience after undergoing robotic surgery for urological cancers, which include prostate, bladder, and kidney cancer. The goal is to understand how the costs associated with treatment affect patients' lives and well-being. Patients who have had robotic surgery within the last year will be contacted by phone or invited to a follow-up visit to participate in the study. They will fill out questionnaires that ask about their personal background, health history, and any challenges they face related to the costs of their treatment.

To be eligible for the trial, participants must be at least 18 years old and have been diagnosed with one of the urological cancers mentioned. They should have undergone robotic surgery in the past twelve months and be willing to sign a consent form to participate. Patients who have serious mental health issues or other ongoing cancers may not be able to take part. Throughout the study, participants can expect to share their experiences and feelings about the financial aspects of their treatment, which will help researchers understand and address these important issues in cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female ≥ 18 years of age;
• • ECOG PS 0-1
• • Diagnosis of urological neoplasm (prostate, bladder and kidney cancer) treated with robotic surgery (robot-assisted prostatectomy, robot-assisted radical cystectomy, robot-assisted radical or partial nephrectomy) in the last twelve months;
• • Subjects willing to sign informed consent.
• Exclusion Criteria:
• • Patients unable to fill out questionnaires (e.g., severe mental illness or cognitive dysfunction);
• • Patients suffering from concomitant malignancies in other sites and in active treatment;
• • Patients with a history of cancer not currently on active treatment may be enrolled.